12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Multiple Sclerosis

Interventions

DRUG

CS-0777 tablets

0.1 mg, once-weekly, for 12 weeks

DRUG

CS-0777 tablets

0.3 mg, once-weekly or once every 2 weeks, for 12 weeks

DRUG

CS-0777 tablets

0.6 mg, once-weekly or once every 2 weeks, for 12 weeks

Trial Locations (5)

Denver

Port Orange

Lenexa

Billings

Philadelphia